Trial · NCT06846086
Cardioprotective Effects of Melatonin in Patients With Cardiomyopathy
NCT06846086, Phase 3, Recruiting, Tanta University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Cardioprotective Effects of Melatonin in Patients With Cardiomyopathy. Trials, record NCT06846086. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06846086
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Cardioprotective Effects of Melatonin in Patients With Cardiomyopathy
- NCT number
- NCT06846086
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 46 participants, estimated
- Lead sponsor
- Tanta University
- Conditions
- Cardiomyopathies
- Interventions
- Melatonin 10 MG, Placebo
- First posted
- 2025-02-25
- Last updated
- 2025-03-26
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Blood Pressure Measurement | baseline , up to 3 month | Unit of Measure: mmHg (Systolic and Diastolic Blood Pressure). • Echocardiography. |
| Primary | Heart Rate (HR) Measurement | baseline, up to 3 month | Unit of Measure: Beats per minute (bpm). |
| Primary | Echocardiographic Parameters | Baseline , up to 3 months. | Parameters Measured: * Left Ventricular Ejection Fraction (LVEF) (%). * Left Ventricular End-Diastolic Diameter (LVEDD) (mm). * Left Ventricular End-Systolic Diameter (LVESD) (mm). GLS % |
| Primary | Echocardiographic Parameters | Baseline , up to 3 months. | Parameters Measured: * Left Ventricular Ejection Fraction (LVEF) (%). * Left Ventricular End-Diastolic Diameter (LVEDD) (mm). * Left Ventricular End-Systolic Diameter (LVESD) (mm). |
| Primary | Serum Concentration of NT Pro- BNP | Baseline, up to 3 months. | Changes in serum B-type Natriuretic Peptide (BNP) concentration from baseline to Week 12. |
| Secondary | composite clinical endpoint score | baseline , up to 3 month | A composite score incorporating the following parameters: * All-cause mortality. * Hospitalization. * Quality of life (QoL) changes, assessed by the Kansas City Cardiomyopathy Questionnaire (KCCQ). • Scoring Details: * Scale Name: Kansas City Cardiomyopathy Questionnaire (KCCQ). * Score Range: 0-100. * Interpretation: Higher scores indicate better quality of life and clinical status, while lower scores indicate worse condition. |
| Secondary | Biochemical Markers | baseline , up to 3 month | * Cardiac biomarkers: Natriuretic peptides (e.g., BNP) for heart stress or damage. * Inflammatory markers: Interleukin-6 (IL-6) which may reflect systemic inflammation. * Antioxidant status: Malondialdehyde (MDA) using commerially available kits. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06846086
GET https://conductscience.org/api/trials/v1/NCT06846086/registered